10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the first quarter ended March 31...
Core Illumina revenue of $1.04 billion for Q1 2025, down 1% from Q1 2024 (flat on a constant currency basis) GAAP operating margin...
Total revenues remain strong at CHF 7.2 billion (CHF 7.3 billion in 2023) Record CHF 833 million raised by privately funded companies drives 22%...
Inventiva , a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic...
Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated resu...
Delivered total first quarter revenue of $707 million, an increase of 11% on a reported and core revenue basis, including Screening revenue of ...
Purchase price of $47 per share in cash represents an enterprise value of €3.0 billion ($3.4 billion), or an equity value of approximately $...
In this exclusive interview with BioPharma BoardRoom, Mike Kadan, PhD, MBA, Chief Operating Officer of Vector BioMed, shares how the company is reimagining...
CEO Paul Hudson: Confidence in Full-Year Outlook Paul Hudson, Chief Executive Officer: “We had a strong start in 2025 with sales growth of 9.7%, b...
- Recorded Q1’25 consolidated revenue of KRW 1.3 trillion - Recorded Q1’25 consolidated operating profit of KRW 486.7 billion - Company exp...
First quarter revenue was $10.36 billion. First quarter GAAP diluted earnings per share (EPS) grew 15% to $3.98. First quarter adjusted EPS gre...
As Asia accounts for nearly half of the world’s cancer burden, the push toward precision medicine is more critical than ever. In this...
Will Tariffs Hit Pharmaceuticals? The Calm Before the Storm While the pharmaceutical industry may have narrowly escaped the latest wave of U.S. ta...
Croda is pleased to announce the appointments of Stephen Oxley as Chief Financial Officer (CFO) and Executive Director, and Dr. Thomas Riermeier as Presi...
© 2025 Biopharma Boardroom. All Rights Reserved.
